GynCongress10 Webcast | prIME Oncology

Faculty

Chairs:

Andreas du Bois, MD, PhD
Dr. Horst-Schmidt-Kliniken
Wiesbaden, Germany

Eric Pujade-Lauraine, MD, PhD
Centre Hospitalier Universitaire Hotel-Dieu
Paris, France

Faculty:

Xavier Bosch, MD, PhD
Institut Catala d'Oncologia
Barcelona, Spain

Andrew Clamp, MD, PhD
Cancer Research UK, Christie Hospital,
United Kingdom

Phillip Harter, MD
Dr. Horst Schmidt Klinik,
Wiesbaden, Germany

Stanley B. Kaye, MD
The Royal Marsden Hospital & Institute of Cancer Research
Sutton, United Kingdom

Fabrice Lécuru, MD, PhD
Hôpital Européen Georges Pompidou
Paris, France

Mansoor R. Mirza, MD
Rigshopitalet, Copenhagen University Hospital
Copenhagen, Denmark

Sandro Pignata, MD, PhD
Istituto Nazionale Tumori
Napoli, Italy

Gordon J.S. Rustin, MD, FRCP
The Clocktower Mount Vernon Hospital
Northwood, United Kingdom

Ignace Vergote, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Webcast Overview

This Webcast contains video and downloadable slides from the 2nd Annual European Gynecologic Oncology Congress and will serve as a valuable forum for the presentation and discussion of newly available data and analyses of ongoing clinical trials thereby providing participants with an update on clinical practice changing therapies in a practical, interactive format, understanding and impacting the care of patients with gynecologic malignancies.

Learning Objectives

After successfully completing this educational activity, participants should be able to:

Assess the impact of human papillomavirus (HPV) vaccines on the screening and prevention of cervical cancer
Develop a practical approach to cervical cancer staging and management of recurrent disease
Discuss the role of surgery and adjuvant radiotherapy in endometrial cancer
Describe the use of systemic therapies in recurrent endometrial cancer
Derive the optimal surgical management of ovarian cancer based on disease stage and clinical presentation
Identify emerging therapies for ovarian cancer and discuss their progress in clinical development
Formulate optimal management strategies for recurrent ovarian cancer
Identify emerging therapies for ovarian cancer and discuss potential impact on the future management practices
Formulate optimal treatment strategies for recurrent ovarian cancer